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The ﬁrst amperometric immunosensor for the quantiﬁcation of TGF-β1, a cytokine proposed as a bio-
marker for patients having or at risk for renal disease, is described in this work. The immunosensor
design involves disposable devices using carboxylic acid-functionalized magnetic microparticles sup-
ported onto screen-printed carbon electrodes and covalent immobilization of the speciﬁc antibody for
TGF-β1 using Mix&Go polymer. A sandwich-type immunoassay was performed using biotin-anti-TGF
and conjugation with peroxidase-labeled streptavidin (poly-HRP-Strept) polymer. Amperometric mea-
surements were carried out at 0.20 V by adding hydrogen peroxide solution onto the electrode surface
in the presence of hydroquinone as the redox mediator. The calibration plot allowed a range of linearity
extending between 15 and 3000 pg/mL TGF-β1 which is adequate for the determination of the cytokine
in plasma and urine. The limit of detection, 10 pg/mL, is notably improved with respect to those obtained
with ELISA kits. The usefulness of the immunosensor for the determination of low TGF-β1 concentrations
in real samples was evaluated by analyzing spiked urine at different pg/mL concentration levels.
& 2016 Elsevier B.V. All rights reserved.1. Introduction
Cytokines are low molecular weight bioactive proteins pro-
duced by many different cells and strongly associated with the
immune system (Stenken and Poschenrieder, 2015) (Liu et al.,
2016). There is enormous clinical interest in cytokines determi-
nation as elevated concentrations of these proteins are associated
with inﬂammation or disease progression and, therefore, various
types of cytokines are widely used as biomarkers to characterize
the immune function, predict diseases and monitor their evolution
and treatments. These applications require the availability of
highly sensitive analytical methods because cytokines appear into
the extracellular milieu at pM concentration range.
The transforming growth factor-β (TGF-β) family is a collection
of structurally related multi-functional cytokines which regulates
a wide range of physiological and pathological processes. They are
involved in cell-growth, rate of proliferation, differentiation and
production of extracellular matrix proteins (Grainger et al., 2000).
Three isoforms (TGF-β1, -β2, and -β3) are present in mammals
with some differences in biological activities and also in their
potencies. Particularly, TGF-β1 is involved in immune and in-
ﬂammatory responses showing a hundred times more potentño).
, E., et al., Biosensors and Bbehavior as growth inhibitor of hematopoeitic stem cells than the
others. This cytokine has been considered as a good biomarker of
liver ﬁbrosis (Fallatah, 2014) or bladder carcinoma (Eder et al.,
1996). Increasing evidence also links TGF-β1 to the progression of
renal ﬁbrosis and scarring associated with diabetic nephropathy or
hypertensive nephrosclerosis (Tsapenko et al., 2013) and glomer-
ulonephritis (Grainger et al., 1995). TGF-β1 concentration levels
between 0.1 and 25 ng/mL have been reported in plasma from
healthy individuals (Grainger et al., 2000). The variability observed
depends to some extent on the assay type used for the determi-
nation. Circulating levels of TGF-β1 increase in patients suffering
various types of cancer in addition to the aforementioned kidney
diseases, and are severely depressed in advanced atherosclerosis
(Matharu et al., 2014).
Despite its importance, relatively few methods are available for
the determination of this cytokine. Immunoassay strategies based
on sandwich-type conﬁgurations with peroxidase-labeled or bio-
tinylated anti-TGF-β1 as detection antibodies are employed in
commercial ELISA colorimetric kits. These methods are valid for
determining TGF-β1 in the range from several tens to thousands of
pg/mL with minimum detectable concentrations that can drop to a
few units of pg/mL. In the particular case of biosensors for TGF-β1
determination, only two conﬁgurations have been found in the
literature. An aptasensor involving aptamer-modiﬁed Au electro-
des integrated with microﬂuidics was reported. Thiolated apta-
mers labeled with methylene blue were self-assembled on goldioelectronics (2016), http://dx.doi.org/10.1016/j.bios.2016.05.093i
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tion limit of 1 ng/mL. This device was used to monitor TGF-β1
release from hepatic cells (Matharu, et al., 2014). Very recently, an
impedimetric immunosensor was developed for the determina-
tion of TGF-β1 in human serum. A self-assembled monolayer of
polyethylene glycol (PEG) prepared onto interdigitated electrodes
was used for the covalent immobilization of the antibodies. A
linear impedance vs log [TGF-β1] range between 1 and 1000
ng/mL was found with a detection limit of 0.570 ng/mL (Yao et al.,
2016). However, biosensors exhibiting higher sensitivity are nee-
ded to be applied to clinical samples containing very low TGF-β1
concentrations. For example, in urine this cytokine ranges typically
between 10 and 50 pg/mL and it has been proposed as a biomarker
for patients having or at risk for renal disease (Tsapenko et al.,
2013) (Grainger et al., 1995) (Honkanen et al., 1997). Obviously, it is
also mostly important the noninvasive nature of collecting urine
sample and therefore its usefulness to be employed with point of
care devices.
In this work, the ﬁrst amperometric immunosensor for the
quantiﬁcation of TGF-β1 is described, with the objective of de-
veloping a sensitive, reliable, and robust analytical tool for the
determination of this cytokine in complex clinical samples. The
immunosensor implies a disposable device using carboxylic acid-
functionalized magnetic microparticles supported onto screen-
printed carbon electrodes. These magnetic beads have demon-
strated to be powerful tools for the preparation of electrochemical
immunosensors enabling minimization of matrix effects in the
analysis of complex samples (Zacco et al., 2006), (Ruiz-Valdepeñas
Montiel et al., 2015). Covalent immobilization of the speciﬁc an-
tibody for TGF-β1 (anti-TGF) was performed using Mix&Go, a
polymer containing several metallic complexes selected for their
efﬁciency to bind proteins (Ojeda et al., 2015). A sandwich-type
immunoassay was designed using biotin-anti-TGF, and conjuga-
tion with peroxidase-labeled streptavidin (poly-HRP-Strept) poly-
mer was used as to amplify the electrochemical detection. Am-
perometric measurements were performed by adding hydrogen
peroxide solution onto the electrode surface in the presence of
hydroquinone as the redox mediator. The analytical usefulness of
the immunosensor was demonstrated by application to urine
samples containing different TGF-β1 concentrations at the pg/mL
level.2. Experimental
2.1. Reagents and solutions
Human TGF–β1, mouse capture antibody (anti-TGF), and
chicken biotinylated antibody (Biotin-anti-TGF) were from R&D
Systems and included in the DuoSet
s
ELISA Development System
(DY240-05). Horseradish peroxidase-labeled streptavidin (HRP-
Strept) (Roche), poly-HRP-Strept (85-R200) (Fitzgerald), carboxylic
acid-functionalized magnetic beads (HOOC-MBs) (Dynabeads
s
M–
270 Carboxylic Acid, 2.8 mm diameter, 30 mg/mL), and Mix&Go™
polymer from Anteo Diagnostics, were also used. Buffer solutions
used were: 0.1 M phosphate buffer solution of pH 8.0 and 0.05 M
phosphate buffer solution of pH 6.0 prepared from Na2HPO4 and
NaH2PO4; saline phosphate buffer of pH 7.2 (PBS) containing
8.1 mM Na2HPO4, 1.5 mM KH2PO4, 137 mM NaCl, and 2.7 mM KCl;
washing buffer solution (WBS) prepared from the latter PBS by
dissolving 0.05% Tween 20; 25 mM MES buffer solution of pH
5.0 prepared from 2–(N–morpholine) ethanosulfonic acid (Gerbu).
Hydrogen peroxide (Aldrich, 30% (w/w) and hydroquinone (Sigma)
were also used. 2 M ethanolamine (Sigma) prepared in 0.1 M
phosphate buffer solution of pH 8.0 was used as blocking solution.
Ascorbic acid (AA) (Fluka), uric acid (UA) and creatinine (CR)Please cite this article as: Sánchez-Tirado, E., et al., Biosensors and B(Sigma), adiponectin (APN), interleukin 6 (IL–6) and interleukin 8
(IL–8) (Abcam), and tumor necrosis factor alpha (TNF–α) (BD
Pharmingen) were tested as potential interferents. Deionized wa-
ter was obtained from a Millipore Milli-Q puriﬁcation system
(18.2 M Ω cm at 25 °C).
2.2. Apparatus and electrodes
Amperometric measurements were performed using an INBEA
potentiostat provided by the IbGraph software. Screen-printed
carbon electrodes (SPCEs, 110 DRP, ϕ 4 mm) from DropSens
(Oviedo, Spain) were used as working electrodes. These electrodes
are provided with a silver pseudo-reference electrode and a car-
bon counter electrode. Incubation steps were performed at 25 °C
using an Optic Ivymen System constant temperature incubator
shaker (Comecta S. A.) and pH measurements were made using a
Crison Basic 20þ pHmeter. A P-Selecta ultrasonic bath, a magnetic
separator (DynaMagns, Invitrogen Dynal), and a Vortex homo-
genizator from Heidolph were also used. All experiments were
performed at room temperature.
2.3. Procedures
2.3.1. Preparation of the poly-HRP-Strept/Biotin-anti-TGF/TGF-β1/
anti-TGF-MBs-conjugates
3 μL of the commercial HOOC-MBs suspension were trans-
ferred into a 1.5 mL Eppendorf tube and washed twice with 50 μL
of MES buffer solution at 25 °C. Each washing step consisted of a
re-suspension of the functionalized MBs in the buffer solution and
stirring at 600 rpm for 10 min (up to homogenization) followed by
magnetic separation for 4 min and removal of the solution. Next,
25 μL of Mix&Go were added and incubated for 60 min at 25 °C
under stirring at 600 rpm. Thereafter, two washing steps with
WBS were carried out and, further, 25 μL of a 5 μg/mL anti–TGF
solution prepared in 25 mM MES buffer solution of pH 5.0 were
added, allowing incubation for 60 min at 25 °C under stirring at
600 rpm. Then, the immunoconjugates were washed ﬁrstly with
50 μL of 25 mM MES buffer solution of pH 5.0 and, secondly, with
50 μL of 100 mM PBS of pH 8.0. Next, a blocking step by incubation
of the anti–TGF-MBs conjugate with 50 μL of 2 M ethanolamine
solution prepared in 0.1 M PBS of pH 8.0 was applied for 1 h.
Thereafter, the excess of ethanolamine was removed by washing
successively with 50 μL of the same PBS buffer and with 50 μL of
the WBS. Bioconjugation of the target cytokine was carried out by
adding 25 μL of a TGF-β1 standard solution or the sample and
incubating for 60 min at 25 °C. Two washings with 50 μL WBS
were performed and 25 μL of a 2 μg/mL Biotin–anti–TGF-β1 so-
lution containing 1% BSA were added and incubated for 60 min at
25 °C under stirring at 600 rpm. Then, two washing steps with
50 μL WBS were applied followed by the addition of 25 μL of 1/
500 diluted poly–HRP–Strept in PBS, and incubation for 20 min.
Finally, two more washing steps with 50 μL WBS were applied. All
buffer solutions used were those recommended by the supplier of
DuoSet
s
ELISA Development System (DY240–05).
2.3.2. Determination of TGF-β1
The as prepared poly-HRP-Strept/Biotin-anti-TGF/TGF-β1/anti-
TGF-MBs were re-suspended in 45 μL of 1 mM hydroquinone and
transferred onto the surface of the SPCE. This was done by keeping
the SPCE horizontal and placing a neodymium magnet on the
bottom part of the electrode to locate in a reproducible way the
biofunctionalized MBs onto the working electrode surface area. A
detection potential of 200 mV was applied and the background
current was recorded until stabilization (100 s approximately).
Further, a 5 µL aliquot of 50 mM hydrogen peroxide solution was
added and, after a period of 200 s for the enzymatic reaction toioelectronics (2016), http://dx.doi.org/10.1016/j.bios.2016.05.093i
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measured.
2.3.3. Analysis of spiked urine
The procedure described above was applied to urine samples
which were spiked with TGF-β1 at ﬁnal concentrations of 25, 45 or
100 pg/mL. No pretreatment was required except a 1:3 dilution
with 0.1 M PBS of pH 7.2. The determination of TGF-β1 was carried
out by interpolation of the amperometric responses for the sam-
ples into the calibration plot constructed with TGF-β1 standards.3. Results and discussion
Fig. 1 shows schematically the different steps involved in the
preparation and functioning of the poly-HRP-Strept/Biotin-anti-
TGF/TGF-β1/anti-TGF-MBs/SPCE immunosensor. Covalent im-
mobilization of capture antibodies onto carboxylic acid-functio-
nalized magnetic microparticles (step 1) was carried out by using
the polymer Mix&Go. This polymer uses ligands to bind Fc do-
mains that mimic those binding domains from proteins A and G
(Ooi et al., 2014), and can also interact strongly with electron
donating moieties such as dissociated carboxyl groups. Therefore,
combination of HOOC-MBs with the use of Mix&Go for antibody
immobilization resulted in a convenient methodology to be ap-
plied as a general route for the preparation of electrochemical
immunosensors (Ojeda et al., 2015). Capture antibodies im-
mobilization was followed by a blocking step with ethanolamine
(step 2) and the implementation of a sandwich-type immunoassay
employing a biotinylated secondary antibody and poly-HRP-Strept
for signal ampliﬁcation (step 3). The use of poly-HRP-Strept in-
stead of conventional HRP-Strept conjugate has demonstrated to
be advantageous for the design of sensitive electrochemical im-
munosensors as multiple HRP molecules are available to biocata-
lyze H2O2 reduction (Ojeda et al., 2014). Once the MBs bearing the
immuno-conjugates were transferred to the surface of SPCE, hy-
drogen peroxide was added (step 4) and the amperometricFig. 1. Schematic display of the different steps involved in the p
Please cite this article as: Sánchez-Tirado, E., et al., Biosensors and Bresponse at 200 mV in the presence of hydroquinone was
measured according to the reactions displayed in Fig. 1.
3.1. Optimization of the experimental variables involved in the pre-
paration of the immunosensor
The effect of the different variables involved in the preparation
of the TGF-β1 immunosensor on the corresponding analytical re-
sponses was studied. The amount of Mix&Go used was that opti-
mized previously in our group (Ojeda et al., 2015) and, in these
studies, conventional HRP-Strep was used to label the detection
antibody since the effect of the other variables should not depend
on the type of label employed.
The anti-TGF loading on the carboxylic acid-functionalized MBs
was optimized by measuring the speciﬁc and unspeciﬁc responses
(without sandwiched antigen) with antibody concentrations ran-
ging between 2.5 and 20 μg/mL. Fig. 2(a) shows as the largest
speciﬁc-to-unspeciﬁc current ratio was obtained for a 5 μg/mL
antibody concentration. Higher concentrations produced a sig-
niﬁcant decrease of the speciﬁc response most likely due to hin-
dering of the electrochemical reaction in the presence of a large
biomolecule loading. Accordingly, such a concentration was se-
lected to construct the immunosensor. Optimization of the in-
cubation time for this step (results not shown) led us to select
60 min for the covalent binding of the antibody.
Ethanolamine was chosen as the blocking agent to minimize
unspeciﬁc adsorptions onto HOOC-MBs after anti-TGF binding due
to its proved efﬁciency for this purpose (Ojeda et al., 2014). In
order to optimize this blocking step, 1 and 2 M ethanolamine so-
lutions and different incubation times over 30–90 min range were
tested. Fig. 2(b) and (c) show as an effective blocking was reached
using a 2 M ethanolamine solution for 60 min. Under these con-
ditions, the current due to unspeciﬁc adsorption was less than 25%
than that measured for such a low TGF-β1 concentration as
125 pg/mL.
The Biotin-anti-TGF concentration was also optimized by test-
ing the electrochemical responses measured with differentreparation of the amperometric immunosensor for TGF-β1.
ioelectronics (2016), http://dx.doi.org/10.1016/j.bios.2016.05.093i
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Fig. 2. Effect of the anti-TGF loading (a), the blocking agent concentration (b), the incubation time in the blocking step (c) and the concentration of Biotin-anti-TGF (d) on the
amperometric response obtained with the TGF-β1immunosensor. 3 μL HOOC-MBs; 25 μL Mix&Go, 60 min; (a) 2.5–20 μg/mL anti-TGF, 60 min; 50 μL 1 M ethanolamine,
90 min; 25 μL 2 mg/mL Biotin–anti–TGF, 60 min; 25 μL 1/2000 dilution HRP-Strept; 20 min; (b) 5 μg/mL anti-TGF, 60 min; 50 μL 1 or 2 M ethanolamine, 90 min; (c) 50 μL 1 M
ethanolamine, 30–90 min; 25 μL 2 mg/mL Biotin–anti–TGF, 60 min; 25 μL 1/2000 dilution HRP-Strept, 20 min; (d) 5 μg/mL anti-TGF, 60 min; 50 μL 1 M ethanolamine, 60 min;
25 μL 1–4 μg/mL Biotin-anti-TGF, 60 min; 25 μL 1/2000 dilution HRP-Strept, 20 min 25 μL 125 pg/mL TGF-β1 (dark grey) and 0 pg/mL TGF-β1 (light grey), 60 min; Eapp¼200
mV. See the text for more information. Triplicate measurements with error bars at 7 s values.
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1-4 μg/mL range. Results obtained (Fig. 2(d)) showed an increase
in the amperometric response with increasing the Biotin-anti-TGF0
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Fig. 3. Comparative responses of the TGF-β1 immunosensor when different loadings of
detection antibody: 25 μL 125 pg/mL TGF-β1 (dark grey) or 0 pg/mL TGF-β1 (light grey), 6
TGF-β1 (light grey), 60 min; 25 μL poly. HRP-Strept, 20 min (b); 3 μL HOOC-MBs; 25 μL M
25 μL 2 μg/mL Biotin-anti-TGF, 60 min (c) amperometric currents for 25 μL of 125 pg/
prepared by covalent immobilization of anti-TGF onto HOOC-MBs using Mix&Go (1) or
25 mg/mL EDC/NHSS, 60 min; 50 μL 2 M ethanolamine, 60 min; 25 μL 2 μg/mL Biotin–an
text for more information. Results for triplicate analysis with error bars at 7 s values.
Please cite this article as: Sánchez-Tirado, E., et al., Biosensors and Bconcentration between 1 and 2 μg/mL. Larger concentrations
produced smaller and rather similar responses suggesting sa-
turation of the antibodies binding sites. Accordingly, 2 μg/mL wasMix&Go EDC/NHSS
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HRP-Strept (a) and poly-HRP-Strept (b) were used to label the biotinylated anti-TGF
0 min; 25 μL HRP-Strept, 20 min (a); 25 μL 60 pg/mL TGF–β1 (dark grey) or 0 pg/mL
ix&Go, 60 min; 25 μL 5 μg/mL anti-TGF, 60 min; 50 μL 1 M ethanolamine, 90 min;
mL (dark grey) or 0 (light grey) TGF–β1, 60 min, measured with immunosensors
by activation with EDC/NHSS (2). 3 μL HOOC-MBs; 25 μL Mix&Go, 60 min or 25 μL
ti–TGF–β1, 60 min; 25 μL, 1/500 poly–HRP–Strept, 20 min; Eapp¼200 mV. See the
ioelectronics (2016), http://dx.doi.org/10.1016/j.bios.2016.05.093i
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cubation time for this step (results not shown), a period of 60 min
was shown be enough to allow binding of all biotinylated anti-
bodies to TGF-β1 antigen.
In order to get the highest possible sensitivity to achieve the goal
mentioned in the Introduction for this work, an electrochemical
signal ampliﬁcation strategy was implemented by labeling the de-
tection antibody with a peroxidase-streptavidin polymer instead of
conventional HRP-Strept. This strategy has demonstrated to enhance
sensitivity in the preparation of electrochemical immunosensors
since multiple HRP molecules are available to be used in the bioca-
talysis of the enzyme substrate (Ojeda et al., 2014). The foreseen
ampliﬁcation effect provoked by the use of poly-HRP-Strept was
conﬁrmed by comparing the responses obtained with both con-
jugates. Fig. 3(a) shows the results when HRP-Strept was employed
with dilution factors ranging from 1/500 to 1/4000. The speciﬁc re-
sponse for a TGF-β1 concentration of 125 pg/mL slightly decreased
when the conjugate concentration was lower while the best speciﬁc-
to-unspeciﬁc current ratio was obtained for a 1/2000 HRP-Strept
dilution. When poly-HRP-Strept was employed, a remarkable larger
current was measured (Fig. 3(b)) for a TGF-β1 concentration of
60 pg/mL, thus demonstrating the achieved ampliﬁcation in the
electrochemical response. In this case, the largest speciﬁc-to-un-
speciﬁc current ratio occurred for a 1/500 dilution factor and, as it
could be expected, it was signiﬁcantly smaller than that occurring
with HRP-Strept. In both cases, an incubation time of 20 min was
enough for binding with the biotinylated secondary antibody.
As commented above, the strategy for binding capture anti-
bodies to carboxylic acid-functionalized MBs implied the use of
the Mix&Go polymer. This was claimed as an efﬁcient strategy for
the stable and oriented binding of antibodies (Ojeda et al., 2015)
and, in this case, it was demonstrated by comparing the im-
munosensor response when anti-TGF antibodies were covalently
immobilized using Mix&Go, with that obtained when conven-
tional EDC/NHSS chemistry was employed for the antibody bind-
ing. As Fig. 3(c) shows, a remarkably enhanced speciﬁc-to-back-
ground current was apparent when anti-TGF was immobilized
using Mix&Go, probably as a consequence of the suitable or-
ientation of the antibody provided by this polymer.
3.2. Analytical characteristics of the immunosensor
Fig. 4 shows the calibration plot for TGF-β1 constructed with
the developed immunosensor under the optimized working0.2
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Fig. 4. Calibration plot construted for TGF-β1 by amperometry at the poly-HRP-Strept/B
for a) 0; b) 2.5; c) 15; d) 30; e) 60; f) 125; g) 250; h) 500; i) 1000; j) 3000 pg/mL TGF-β
Please cite this article as: Sánchez-Tirado, E., et al., Biosensors and Bconditions. Error bars were calculated from measurements carried
out with three different immunosensors in each case. The steady
state current vs. logarithm of TGF-β1 concentration followed the
adjusted equation I(nA)¼978 log C(pg/mL)734 (r2¼0.991), with
a range of linearity extending between 15 and 3000 pg/mL TGF-β1.
This range covers more than two orders of magnitude and it is
adequate for the determination of the cytokine in real samples
taking into account the expected concentrations, at ng/mL level in
plasma (Grainger et al., 1995), or tens of pg/mL in urine (Tsapenko
et al., 2013). The limit of detection, 10 pg/mL, was calculated by
applying the 3 sb criterion, where sb was estimated as the standard
deviation in concentration units (n¼10) of measured blank cur-
rents (0 ng/mL TGF-β1). The analytical characteristics achieved
with the proposed immunosensor improve notably those reported
for the commercial ELISA kits. For example, RayBio
s
Human TGF-
beta1 ELISA kit (ELH-TGFb1) claims (〈www.raybiotech.com/ﬁles/
manual/ELISA/ELH-TGFb1.pdf〉) for a minimun detectable dose
(analyte concentration resulting in an absorbance equal to 2 s
higher than that of the blank) of 80 pg/mL, which is eight times
higher than that achieved in this work. The immunosensor ex-
hibits also remarkably higher sensitivity than that reported for
both the aptasensor (LOD of 1 ng/mL) (Honkanen et al., 1997) and
the impedimetric imunosensor (LOD ¼0.570 ng/mL) (Yao et al.,
2016).
The reproducibility of the amperometric responses obtained
with different immunosensors was evaluated. Sets of immuno-
sensors were prepared on the same day and on different days using
a new anti-TGF-MBs/SPCE in each case. The relative standard de-
viation (RSD) (n¼5) values were 2.9% and 3.9% for the assays per-
formed on the same day in the absence and in the presence of
250 pg/mL TGF-β1, respectively, whereas RSD (n¼5) values were
3.7% and 4.2%, respectively, for the measurements made on different
days. These results revealed the good level of precision achieved in
the fabrication and functioning of the proposed immunosensing
platform. Moreover, the storage ability of anti-TGF-MBs/SPCE con-
jugates was also tested. Different anti-TGF-MBs/SPCE were prepared
on the same day, stored under humidity conditions at 4 °C, and
employed to prepare immunosensors to measure 250 pg/mL TGF-
β1 on different days. The results obtained (not shown) indicated
that the immunosensor responses remained within the control
limits, located at 73 s, were s was the standard deviation of the
measurements (n ¼10) carried out on the ﬁrst working day, for at
least 30 days (no longer storage times were tested) demonstrating
the good stability of the anti-TGF-MBs/SPCE conjugates.0 100 200 300 400
1 μA
me, s
a 
j
↓
 
iotin-anti-TGF/TGF-β1/anti-TGF-MBs/SPCE immunosensor. Amperograms recorded
1. Dotted line indicates the time of measurement.
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Fig. 5. Amperometric responses measured with the poly-HRP-Strept/Biotin-anti-
TGF/TGF-β1/anti-TGF-MBs/SPCE immunosensor for 0 (light grey) and 25 pg/mL
TGF-β1 (dark grey) in the presence of 370 μg/mL ascorbic acid (AA), 50 μg/mL uric
acid (AU), 200 pg/mL adiponectin (APN), 10 pg/mL creatinine (CR), 200 pg/mL tu-
mor necrosis factor alpha (TNF), 500 pg/mL interleukin 6 (IL-6), and 10 ng/mL in-
terleukin 8 (IL-8).
Table 1
Determination of TGF-β1 in spiked urine with the poly-HRP-Strept/Biotin-anti-TGF/
TGF-β1/anti-TGF-MBs/SPCE immunosensor.
TGF-β1, pg/mL TGF-β1found, pg/mL Recovery, %
25 25.970.5 10378
45 44.970.3 10073
100 9671 9775
E. Sánchez-Tirado et al. / Biosensors and Bioelectronics ∎ (∎∎∎∎) ∎∎∎–∎∎∎6The used antibody also exhibited a great selectivity against
other proteins. Fig. 5 displays the immunosensor responses in the
absence and in the presence of 25 pg/mL TGF-β1, and in the pre-
sence of ascorbic acid (AA), uric acid (UA), adiponectin (APN),
creatinine (CR), tumor necrosis factor alpha (TNF), interleukin 6
(IL-6) or interleukin 8 (IL-8) at the expected concentrations in
healthy patients. As it is clearly seen, no signiﬁcant differences
were apparent in any case. Interestingly, due to the detection po-
tential value used, no interference from electroactive substances
such as ascorbic and uric acids was observed.
3.3. Determination of TGF-β1 in spiked urine
The usefulness of the immunosensor for the determination of
low TGF-β1 concentrations in real samples was evaluated by
analyzing spiked urine following the procedure described in sec-
tion 2.3.3. The sample used was Liquichek™ Urine Chemistry
Control (BioRad) containing uric acid, amilase, calcium, chloride,
cortisol, creatinine, phosphorous, glucose, magnesium, albumin,
potassium, sodium, and urea, and it was spiked with TGF-β1 at 25,
45 or 100 pg/mL concentration levels.
The possibility of a matrix effect was evaluated by constructing
calibration graphs in urine by spiking it with TGF-β1 concentra-
tions ranging between 25 and 250 pg/mL and applying 0, 1:2 and
1:3 dilution ratios with 0.1 M PBS of pH 7.2. The results obtained
revealed that a 1:3 dilution was enough to avoid signiﬁcant matrix
effects since the slope of the calibration plot, 911 nA per decade of
concentration, was not statistically different from that obtained
with TGF-β1 standards. Accordingly, the determination of TGF-β1
in urine could be accomplished by interpolation of the current
measured with the immunosensor in the 1:3 diluted samples into
calibration plot prepared with standards. No other sample pre-
treatment was needed in any case. Table 1 summarizes the results
obtained in the analysis of spiked urine with recoveries near to
100% in all cases, thus demonstrating the suitability of thePlease cite this article as: Sánchez-Tirado, E., et al., Biosensors and Bapproach to determine low TGF-β1 concentrations in a complex
biological ﬂuid such urine is.4. Conclusions
The ﬁrst amperometric immunosensor for the quantiﬁcation of
the cytokine TGF-β1, proposed as a biomarker for patients having
or at risk for renal disease, is described in this work. The rational
design of the immunosensor involving stable and oriented im-
mobilization of the speciﬁc antibodies on carboxylic acid-func-
tionalized MBs by using the polymer Mix&Go, and an electro-
chemical signal ampliﬁcation strategy by labeling the detection
antibody with a peroxidase-streptavidin polymer, allowed re-
markably improved analytical characteristics to be obtained with
respect to ELISA kits or previous methods. Combining these ben-
eﬁts, a calibration plot suitable for the determination of the cy-
tokine in plasma and urine is achieved. This allowed the de-
termination of TGF-β1 concentrations in urine at the pg/mL con-
centration level with no sample treatment except a 1:3 dilution
with buffer solution. The obtained results show that the initial
objective of developing a sensitive, reliable, and robust analytical
tool for the determination of this cytokine in complex clinical
samples, and, therefore, suitable to develop point-of-care devices
is reasonably achieved.Acknowledgments
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